Alnylam Pharmaceuticals (ALNY) Convertible Debt (2022 - 2026)

Alnylam Pharmaceuticals (ALNY) has 5 years of Convertible Debt data on file, last reported at $1.0 billion in Q1 2026.

• For the quarter ending Q1 2026, Convertible Debt fell 1.58% year-over-year to $1.0 billion; the trailing twelve-month figure through Mar 2026 stood at $1.0 billion (down 1.58% YoY), and the FY2025 full-year result was $1.0 billion, down 1.64% from the prior year.
• Convertible Debt for Q1 2026 stood at $1.0 billion, roughly flat from $1.0 billion in the prior quarter.
• Across five years, Convertible Debt topped out at $1.0 billion in Q3 2025 and bottomed at $1.0 billion in Q4 2025.
• The 5-year median for Convertible Debt is $1.0 billion (2023), against an average of $1.0 billion.
• Peak annual rise in Convertible Debt reached 1.62% in 2025, while the deepest fall reached 1.64% in 2025.
• A 5-year view of Convertible Debt shows it stood at $1.0 billion in 2022, then rose by 0.38% to $1.0 billion in 2023, then gained by 0.38% to $1.0 billion in 2024, then decreased by 1.64% to $1.0 billion in 2025, then gained by 0.16% to $1.0 billion in 2026.
• The last three Convertible Debt figures came in at $1.0 billion (Q1 2026), $1.0 billion (Q4 2025), and $1.0 billion (Q3 2025), per Business Quant data.

Peer Comparison